Jazz Pharmaceuticals sales in 2021-2023, by therapy area
In 2023, Jazz Pharmaceuticals reported around 2.7 billion U.S. dollars in total sales for its neuroscience products, to a large part generated from oxybate products Xyrem and Xywav. This statistic illustrates the total sales of Jazz Pharmaceuticals worldwide from 2021 to 2023, by therapy area. Jazz Pharmaceuticals is a California-originated, but today Ireland-based biopharma company.